These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17570760)

  • 21. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice.
    Lu H; Xu XF; Gao N; Fan DY; Wang J; An J
    Mol Immunol; 2013 Jun; 54(2):109-14. PubMed ID: 23270684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge.
    Men R; Wyatt L; Tokimatsu I; Arakaki S; Shameem G; Elkins R; Chanock R; Moss B; Lai CJ
    Vaccine; 2000 Jul; 18(27):3113-22. PubMed ID: 10856791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity.
    Chiang CY; Hsieh CH; Chen MY; Tsai JP; Liu HH; Liu SJ; Chong P; Leng CH; Chen HW
    Vaccine; 2014 Mar; 32(12):1346-53. PubMed ID: 24486311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
    Apt D; Raviprakash K; Brinkman A; Semyonov A; Yang S; Skinner C; Diehl L; Lyons R; Porter K; Punnonen J
    Vaccine; 2006 Jan; 24(3):335-44. PubMed ID: 16125280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
    Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
    Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
    Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-response study in mice of a tetravalent recombinant dengue envelope domain III protein secreted from insect cells.
    Shao L; Pang Z; Bi Y; Li Z; Lin W; Li G; Guo Y; Qi J; Niu G
    Infect Genet Evol; 2020 Nov; 85():104427. PubMed ID: 32565359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
    De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
    Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
    Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
    Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing antibodies respond to a bivalent dengue DNA vaccine or/and a recombinant bivalent antigen.
    Zhang ZS; Weng YW; Huang HL; Zhang JM; Yan YS
    Mol Med Rep; 2015 Feb; 11(2):1009-16. PubMed ID: 25371092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice.
    Gao N; Li J; Sheng Z; Chen H; Fan D; Wang P; An J
    Appl Microbiol Biotechnol; 2019 Jun; 103(12):4977-4986. PubMed ID: 31037380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dengue-1 envelope protein domain III produced in Pichia pastoris: potential use for serological diagnosis.
    Cardoso SA; Paixão VF; Oliveira MD; Honda ER; Oliveira LL; da Silva CC; De Paula SO
    Protein Expr Purif; 2013 Nov; 92(1):9-13. PubMed ID: 23993978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
    Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
    Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice.
    Chen W; Kawano H; Men R; Clark D; Lai CJ
    J Virol; 1995 Aug; 69(8):5186-90. PubMed ID: 7609092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus.
    Suzarte E; Marcos E; Gil L; Valdés I; Lazo L; Ramos Y; Pérez Y; Falcón V; Romero Y; Guzmán MG; González S; Kourí J; Guillén G; Hermida L
    Arch Virol; 2014 Jul; 159(7):1629-40. PubMed ID: 24420159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
    Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
    Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of a Candidate DNA Vaccine Based on the prM/E Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain.
    Putri DH; Sudiro TM; Yunita R; Jaya UA; Dewi BE; Sjatha F; Konishi E; Hotta H; Sudarmono P
    Jpn J Infect Dis; 2015; 68(5):357-63. PubMed ID: 25766602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice.
    Lazo L; Zulueta A; Hermida L; Blanco A; Sánchez J; Valdés I; Gil L; López C; Romero Y; Guzmán MG; Guillén G
    Biotechnol Appl Biochem; 2009 Apr; 52(Pt 4):265-71. PubMed ID: 18636968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.